HYPERBARIC OXYGENATION AS THE PRETREATMENT AND THERAPY IN ISCHEMIA-REPERFUSION INJURY
Abstract
Tissue ischemia means insufficient blood flow to a certain area of the body. Interruption of the arterial blood supply leads to an imbalance between metabolic supply and demand and the development of tissue hypoxia. Tissue hypoxia induces metabolic changes that result in inflammation, increased production of reactive oxygen species, and cell death. If adequate blood flow is established in the ischemic tissue, there will be an increase in cellular damage, which is referred to as ischemic-reperfusion injury. Ischemia and ischemia-reperfusion injury are at the root of numerous diseases widely present in modern society, such as myocardial infarction, cerebral insult, acute kidney injury. For now, there is no way to directly affect cellular hypoxia, but the clinical treatment of hypoxic conditions is aimed at modulating global hypoxemia and increasing the amount of oxygen dissolved in the blood. Hyperbaric oxygenation (HBO) is a treatment during which the patient breathes 100% oxygen under a pressure of at least 1.4 atmospheres. Although the use of hyperbaric therapy was recorded as early as the 17th century, today this treatment is approved for a few indications.
References
1. Atanacković M, Bacetić D, Basta-Jovanović G, Begić-Janeva A, Boričić I, Brašanac D, et al. Patologija. 5th ed. Beograd: Medicinski fakultet Univerziteta u Beogradu, Katedra za patologiju; 2015.
2. Pešić BČ. Patofiziologija: mehanizmi poremećaja zdravlja I deo. 1st ed. Beograd: Medicinski fakultet Univerziteta u Beogradu, CIBID; 2015.
3. Penttila A, Trump B. Studies on the modification of the cellular response to injury. Virchows Archiv B Cell Pathology 1975; 18(1):17-34.
4. Francis A, Baynosa R. Ischaemia-reperfusion injury and hyperbaric oxygen pathways: a review of cellular mechanisms. Diving Hyperb Med 2017; 47(2):110-7. doi: 10.28920/dhm47.2.110-117.
5. Sánchez E. Pathophysiology of ischemia-reperfusion injury and its management with hyperbaric oxygen (HBO): a review. J Emerg Crit Care Med 2019; 3:22. doi: 10.21037/jeccm.2019.04.03
6. Heusch G. Critical Issues for the Translation of Cardioprotection. Circ Res 2017; 120(9):1477-86. doi: 10.1161/CIRCRESAHA.117.310820.
7. Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol 2015; 65(14):1454-71. doi: 10.1016/j.jacc.2015.02.032. PMID: 25857912.
8. Lee JW, Ko J, Ju C, Eltzschig HK. Hypoxia signaling in human diseases and therapeutic targets. Exp Mol Med 2019; 51(6):1-13. doi: 10.1038/s12276-019-0235-1.
9. Hentia C, Rizzato A, Camporesi E, Yang Z, Muntean DM, Săndesc D, et al. An overview of protective strategies against ischemia/reperfusion injury: The role of hyperbaric oxygen preconditioning. Brain Behav 2018; 8(5):e00959. doi: 10.1002/brb3.959.
10. García-Covarrubias L, Sánchez-Rodríguez EC. Hyperbaric oxygenation therapy, basic concepts. Gac Med Mex 2000; 136(1):45-56.
11. Živković M. Priručnik za hiperbaričnu medicinu. Beograd: Srpska zdravstvena organizacija; 2010.
12. FDA- Food and Drug Administration. Available at: www.fda.gov (20.08.2022.).
13. Francis A, Baynosa R. Ischaemia-reperfusion injury and hyperbaric oxygen pathways: a review of cellular mechanisms. Diving Hyperb Med 2017; 47(2):110-7. doi: 10.28920/dhm47.2.110-117.
14. Wang L, Li W, Kang Z, Liu Y, Deng X, Tao H, et al. Hyperbaric oxygen preconditioning attenuates early apoptosis after spinal cord ischemia in rats. J Neurotrauma 2009; 26(1):55-66. doi: 10.1089/neu.2008.0538.
15. Wu MY, Yiang GT, Liao WT, Tsai AP, Cheng YL, Cheng PW, et al. Current Mechanistic Concepts in Ischemia and Reperfusion Injury. Cell Physiol Biochem 2018; 46(4):1650-67. doi: 10.1159/000489241.
16. Granger DN, Kvietys PR. Reperfusion injury and reactive oxygen species: The evolution of a concept. Redox Biol 2015; 6:524-51. doi: 10.1016/j.redox.2015.08.020. Epub 2015 Oct 8.
17. Chung HY, Baek BS, Song SH, Kim MS, Huh JI, Shim KH, et al. Xanthine dehydrogenase/xanthine oxidase and oxidative stress. Age (Omaha) 1997; 20(3):127-40. doi: 10.1007/s11357-997-0012-2.
18. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008; 31(Suppl 2):S170-80. doi: 10.2337/dc08-s247.
19. Sedeek M, Nasrallah R, Touyz RM, Hébert RL. NADPH oxidases, reactive oxygen species, and the kidney: friend and foe. J Am Soc Nephrol 2013; 24(10):1512-8. doi: 10.1681/ASN.2012111112.
20. Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol 2000; 190(3):255-66. doi:10.1002/(SICI)10969896(200002)190:3<255:AID-PATH526>3.0.CO;2-6.
21. Granger DN, Korthuis RJ. Physiologic mechanisms of postischemic tissue injury. Annu Rev Physiol 1995; 57:311-32. doi: 10.1146/annurev.ph.57.030195.001523. PMID: 7778871.
22. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J 2012; 33(7):829-37. doi: 10.1093/eurheartj/ehr304.
23. Kirby JP, Snyder J, Schuerer DJE, Peters JS, Bochicchio GV. Essentials of Hyperbaric Oxygen Therapy: 2019 Review. Mo Med 2019; 116(3):176-9.
24. Ortega MA, Fraile-Martinez O, García-Montero C, Callejón-Peláez E, Sáez MA, Álvarez-Mon MA, et al. A General Overview on the Hyperbaric Oxygen Therapy: Applications, Mechanisms and Translational Opportunities. Medicina (Kaunas) 2021; 57(9):864. doi: 10.3390/medicina57090864.
25. Hentia C, Rizzato A, Camporesi E, Yang Z, Muntean DM, Săndesc D, Bosco G. An overview of protective strategies against ischemia/reperfusion injury: The role of hyperbaric oxygen preconditioning. Brain Behav 2018; 8(5):e00959. doi: 10.1002/brb3.959.
26. Hu SL, Feng H, Xi GH. Hyperbaric oxygen therapy and preconditioning for ischemic and hemorrhagic stroke. Med Gas Res 2016; 6(4):232-6. doi: 10.4103/2045-9912.196907.
27. Hu Q, Manaenko A, Matei N, Guo Z, Xu T, Tang J, et al. Hyperbaric oxygen preconditioning: a reliable option for neuroprotection. Med Gas Res. 2016 Apr 4;6(1):20-32. doi: 10.4103/2045-9912.179337.
28. Kovacevic S, Ivanov M, Brkic P, Vajic UJ, Mihailovic-Stanojevic N, Nesovic-Ostojic J et al. Hyperbaric oxygen preconditioning and the role of NADPH oxidase inhibition in postischemic acute kidney injury induced in spontaneously hypertensive rats. PLoS One 2020; 15(1):e0226974. doi: 10.1371/journal.pone.0226974.
29. Nesovic Ostojic J, Ivanov M, Mihailovic-Stanojevic N, Karanovic D, Kovacevic S, Brkic P, et al. Hyperbaric Oxygen Preconditioning Upregulates Heme OxyGenase-1 and Anti-Apoptotic Bcl-2 Protein Expression in Spontaneously Hypertensive Rats with Induced Postischemic Acute Kidney Injury. Int J Mol Sci 2021; 22(3):1382. doi: 10.3390/ijms22031382.
30. Losada DM, Jordani ME, Jordani MC, Piccinato MA, Fina CF, Feres O, et al. Should preconditioning hyperbaric oxygenation protect the liver against ischemia-reperfusion injury? An experimental study in a rat model. Transplant Proc 2014; 46(1):56-62. doi: 10.1016/j.transproceed.2013.10.044.
31. Losada DM, Chies AB, Feres O, Chaib E, D'Albuquerque LA, Castro-e-Silva O. Effects of hyperbaric oxygen therapy as hepatic preconditioning in rats submitted to hepatic ischemia/reperfusion injury. Acta Cir Bras 2014; 29(Suppl 2):61-6. doi: 10.1590/s0102-8650201400140012.
32. Xiao YD, Liu YQ, Li JL, Ma XM, Wang YB, Liu YF, et al. Hyperbaric oxygen preconditioning inhibits skin flap apoptosis in a rat ischemia-reperfusion model. J Surg Res 2015; 199(2):732-9. doi: 10.1016/j.jss.2015.06.038.
33. Sunami K, Takeda Y, Hashimoto M, Hirakawa M. Hyperbaric oxygen reduces infarct volume in rats by increasing oxygen supply to the ischemic periphery. Crit Care Med 2000; 28(8):2831-6. doi: 10.1097/00003246-200008000-00025.
34. Hu SL, Feng H, Xi GH. Hyperbaric oxygen therapy and preconditioning for ischemic and hemorrhagic stroke. Med Gas Res 2016; 6(4):232-6. doi: 10.4103/2045-9912.196907.
35. Sharma R, Sharma SK, Mudgal SK, Jelly P, Thakur K. Efficacy of hyperbaric oxygen therapy for diabetic foot ulcer, a systematic review and meta-analysis of controlled clinical trials. Sci Rep 2021; 11(1):2189. doi: 10.1038/s41598-021-81886-1